Targeting EGFR in glioblastoma: lessons from a disappointing journey. A systematic review
OncologiaSobre o estudo
- Desenho
- Revisão sistemática
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- Journal of neurosurgical sciences
- Publicado em
- 26 mar 2026
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Targeting EGFR in glioblastoma: lessons from a disappointing journey. A systematic review
Ali Berro, Ahmad Assi, Sarah Samhat, Grace Sabra, Rita Haddad, Yara Gebran, Ronald Moussa
Descritores MeSH
- Glioblastoma
- Antineoplastic Agents
- Brain Neoplasms
- Protein Kinase Inhibitors
- ErbB Receptors
- Erlotinib Hydrochloride
- Humans
Veja também
Estudos relacionados
- The safety and efficacy of tyrosine kinase inhibitors against EGFR in patients with glioma; A systematic review, meta-analysis, and sub-group analysis on glioblastoma
- The efficacy of combination therapy versus monotherapy in patients with glioblastoma with abnormal epidermal growth factor receptor (EGFR) genes, a systematic review and network meta-analysis
- Protein kinase inhibitors as targeted therapy for glioblastoma: a meta-analysis of randomized controlled clinical trials
- Meta-analysis of Targeted Therapies in EGFR-mutated Non-Small Cell Lung Cancer: Efficacy and Safety of Osimertinib, Erlotinib, and Gefitinib as First-line Treatment